Leah Brincefield-Wermer
Nurse Practitioner · New Haven, INNPI 1437783719
Payments from drug & device makers
Across 110 payments — averaging $16.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$458
- AbbVie$324
- AstraZeneca$176
- Bayer$170
- Lilly USA, LLC$123
- Boehringer Ingelheim$90
- plus $519 from 17 others
What the payments were for
- Food & beverage$1,859100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 26 | $458 |
| AbbVie | 21 | $324 |
| AstraZeneca | 10 | $176 |
| Bayer | 9 | $170 |
| Lilly USA, LLC | 8 | $123 |
| Boehringer Ingelheim | 5 | $90 |
| Johnson & Johnson | 4 | $80 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $58 |
| Axsome Therapeutics, Inc. | 3 | $52 |
| Exact Sciences | 3 | $52 |
| Xeris Pharmaceuticals, Inc. | 3 | $47 |
| Merck | 2 | $31 |
| Amgen | 2 | $27 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $26 |
| Amarin Pharma, Inc. | 1 | $23 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $20 |
| Corcept Therapeutics | 1 | $19 |
| Idorsia Pharmaceuticals US Inc | 1 | $16 |
| Dynavax Technologies Corporation | 1 | $15 |
| Paratek Pharmaceuticals, Inc. | 1 | $14 |
| GSK | 1 | $14 |
| Astellas Pharma US Inc | 1 | $13 |
| Pfizer | 1 | $13 |
How this compares
$1,859 in reported general payments places this provider in the 80th percentile of 2,724 nurse practitioner providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 32 | $43,113 |
| JanuviaSitagliptin Phosphate | 43 | $41,259 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 27 | $37,753 |
| JardianceEmpagliflozin | 16 | $26,267 |
| MounjaroTirzepatide | 12 | $25,061 |
| FarxigaDapagliflozin Propanediol | 17 | $24,859 |
| RybelsusSemaglutide | 13 | $21,630 |
| InvokanaCanagliflozin | 15 | $15,328 |
| Breo ElliptaFluticasone/Vilanterol | 24 | $13,884 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 33 | $4,674 |
| Omeprazole | 170 | $2,447 |
| SynthroidLevothyroxine Sodium | 39 | $2,395 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 18 | $2,324 |
| Levothyroxine Sodium | 241 | $2,188 |
| Atorvastatin Calcium | 406 | $1,932 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $458 | $64,74445 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $14 | $51,63751 claims |
| MerckJanuvia | $31 | $41,25943 claims |
| Boehringer IngelheimJardiance | $90 | $26,26716 claims |
| Lilly USA, LLCMounjaro | $123 | $25,06112 claims |
| AstraZenecaFarxiga | $176 | $24,85917 claims |
| Johnson & JohnsonInvokana | $80 | $15,32815 claims |
| AbbVieSynthroid | $324 | $2,39539 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,724 nurse practitioner providers in Indiana.
Other nurse practitioner in New Haven
- Kristi OrbaughIndianapolis$1.3M
- Kimberly EadsPlainfield$302K
- Sean GoddardFort Wayne$180K
- Kacy RogersIndianapolis$77K
- Kristine TaylorFort Wayne$69K
- Brittany SavageIndianapolis$51K
- Monica HaugerTrafalgar$47K
- Rhonda HettingerClarksville$38K
- Jennifer MaahsIndianapolis$36K
- Amber MillerLawrenceburg$32K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.